Abstracts tagged "juvenile arthritis and therapeutic targeting"

Abstract Number: 933 • 2015 ACR/ARHP Annual Meeting
DEK-Targeting DNA Aptamers As Novel Therapeutics for Inflammatory Arthritis
Nirit Mor-Vaknin¹, Anjan K. Saha², Maureen Legendre¹, Carmelo Carmona-Rivera³, M. Asif Amin⁴, Bradley J. Rabquer⁵, Marta J. Gonzalez-Hernandez⁶, Julie M. Jorns⁷, Srilakshmi Yalavarthi⁸, Smriti Mohan⁹, Dave Pai¹⁰, Kristine Angevine¹¹, Barbara Adams¹², Jason S. Knight⁸, Alisa E. Koch^13,14,15, David Fox¹⁴, Dave Engelke¹⁶, Mariana J. Kaplan¹⁷ and David Markovitz⁴, ¹Infectious Diseases, University of Michigan, Ann Arbor, MI, ²Medical School, University of Michigan, Ann Arbor, MI, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Internal Medicine, University of Michigan, Ann Arbor, MI, ⁵Albion College, Ann Arbor, MI, ⁶Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, ⁷Pathology, University of Michigan, Ann Arbor, MI, ⁸Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ¹⁰Scripps Research Institute, San Diego, CT, ¹¹Appistry, Inc, St. Louis, MO, ¹²Pediatric Rheum PTD, Univ of Michigan Hlth System, Ann Arbor, MI, ¹³VA Medical Service, Ann Arbor, MI, ¹⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ¹⁵Internal Medicine, Veteran's Affairs and University of Michigan, Ann Arbor, MI, ¹⁶Biochemistry, University Michigan, Ann Arbor, MI, ¹⁷Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Aptamers are short single stranded DNA or RNA oligonucleotides that are specifically selected to bind and neutralize a wide range of biomedically relevant proteins.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].